The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • There was no gene found in the curated document received from the VCI/VCEP
  • Gene listed was thus derived from ClinVar and/or CAR
  • The variant label for this record ("m.3256C>T") does not appear to be in HGVS format


Variant: m.3256C>T

CA120561

9591 (ClinVar)

Gene: MT-TL1
Condition: mitochondrial disease
Inheritance Mode: Mitochondrial inheritance
UUID: 688c9d1e-0184-408b-b6a9-bacbc35043f6

HGVS expressions

NC_012920.1:m.3256C>T
J01415.2:m.3256C>T

Likely Pathogenic

Met criteria codes 5
PM2_Supporting PS4_Moderate PP1 PP3 PS3_Supporting
Not Met criteria codes 2
PS2 PM6

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Mitochondrial Disease Nuclear and Mitochondrial Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1_mtDNA

PDF
Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Mitochondrial Diseases VCEP
The m.3256C>T variant in MT-TL1 has been reported in four individuals in the literature and an additional four cases were seen by experts on this panel. Affected individuals had primary mitochondrial disease with variable features including MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) phenotype, neurologic involvement (neurodegeneration/dementia, stroke-like episodes, recurrent encephalopathy, seizures, ataxia, myoclonus); neuromuscular involvement (muscle atrophy, progressive myopathy); cardiac involvement (cardiac failure); ophthalmologic involvement (ophthalmoplegia, ptosis, central vision loss); ENT involvement (hearing loss); endocrine involvement (hashimoto thyroiditis, diabetes mellitus); lab abnormalities (elevated blood and CSF lactate and pyruvate); and brain imaging findings (progressive brain atrophy); with heteroplasmy levels in multiple tissues ranging from 8% - 98% (PS4_moderate; PMIDs: 19941338, 10953207, 7804130, 8254046). This variant segregated with disease in a single reported family as the proband’s healthy sister had undetectable levels of variant in blood; the proband’s mother was decreased; and the proband was heteroplasmic for the variant in numerous tissues: 64% (muscle), 8% (white blood cells), 48% (first passage cultured fibroblasts), and 18% (hair roots) (PP1; PMID: 8254046). There are no reports of de novo occurrences of this variant to our knowledge. Ragged red fiber (RRF) analysis in muscle noted only partially impaired COX activity. However, when analyzed for levels of mutant genomes, RRFs were essentially homoplasmic for mutant mtDNAs (range 94-97%). Normal (non-RRFs) had much lower levels of mutant genomes (34-75%). The percentage of mutant mtDNA in total the muscle was 64% (PS3_supporting: PMID: 8254046). This variant is absent from Mitomap's 51,863 sequences (AF=0.00%); Helix's 196,554 sequences (AF=0.00%); and gnomAD v3.1.2 (PM2_supporting). The computational predictor MitoTIP suggests this variant impacts the function of this tRNA with a score of 93.70%, as does HmtVar with a score of 0.75 (PP3). In summary, this variant meets criteria to be classified as likely pathogenic for primary mitochondrial disease inherited in a mitochondrial manner. We note that some experts on this panel voted for a classification of pathogenic given the overwhelming evidence of pathogenicity (strong single fiber studies, absent in population databases and present in eight individuals with features of primary mitochondrial disease). This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on August 8, 2022. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID: 32906214): PS4_moderate, PM2_supporting, PP3, PP1, PS3_supporting
Met criteria codes
PM2_Supporting
This variant is absent from Mitomap's 51,863 sequences (AF=0.00%); Helix's 196,554 sequences (AF=0.00%); and gnomAD v3.1.2.
PS4_Moderate
The m.3256C>T variant in MT-TL1 has been reported in four individuals in the literature and an additional four cases were seen by experts on this panel. Affected individuals had primary mitochondrial disease with variable features including MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) phenotype, neurologic involvement (neurodegeneration/dementia, stroke-like episodes, recurrent encephalopathy, seizures, ataxia, myoclonus); neuromuscular involvement (muscle atrophy, progressive myopathy); cardiac involvement (cardiac failure); ophthalmologic involvement (ophthalmoplegia, ptosis, central vision loss); ENT (hearing loss); endocrine involvement (hashimoto thyroiditis, diabetes mellitus); lab abnormalities (elevated blood and CSF lactate and pyruvate); and brain imaging findings (progressive brain atrophy); with heteroplasmy levels in multiple tissues ranging from 8% - 98% (PS4_moderate; PMIDs: 19941338, 10953207, 7804130, 8254046).
PP1
This variant segregated with disease in the single reported family as the proband’s healthy sister had undetectable levels of variant in blood, the mother was deceased. The proband was heteroplasmic for the variant in numerous tissues: 64% (muscle), 8% (white blood cells), 48% (first passage cultured fibroblasts), and 18% (hair roots) (PMID: 8254046).
PP3
The computational predictor MitoTIP suggests this variant impacts the function of this tRNA with a score of 93.70%, as does HmtVar with a score of 0.75.
PS3_Supporting
Ragged red fiber (RRF) analysis in muscle noted only partially impaired COX activity. However, when analyzed for levels of mutant genomes, RRFs were essentially homoplasmic for mutant mtDNAs (range 94-97%). Normal (non-RRFs) had much lower levels of mutant genomes (34-75%). The percentage of mutant mtDNA in total the muscle was 64% (PS3_supporting: PMID: 8254046).
Not Met criteria codes
PS2
No de novo cases reported in the literature but there was limited maternal family testing.
PM6
No assumed de novo cases reported in the literature but there was limited maternal family testing.
Approved on: 2022-08-08
Published on: 2022-10-13
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.